高级检索
当前位置: 首页 > 详情页

Valeric acid acts as a novel HDAC3 inhibitor against prostate cancer

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Department of Chinese Medicine, Naval Medical University, Shanghai 200433, People’s Republic of China [2]Department of Chinese Medicine Oncology, Changhai Hospital affiliated to Naval Medical University, Shanghai 200433, People’s Republic of China [3]Beijing University of Traditional Chinese Medicine, Beijing 100700, People’s Republic of China [4]Department of Integrated Chinese and Western Medicine & Geriatric Oncology, Peking University Cancer Hospital, Beijing 100142, People’s Republic of China [5]Department of Oncology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510405, Guangdong, People’s Republic of China [6]Present Address: Department of Chronic Disease Epidemiology, Yale School of Public Health, Yale University, 60 College Street, New Haven, CT 06520‑8034, USA [7]School of Medicine, Center for Biomedical Data Science, Yale University, 60 College Street, New Haven, CT 06520‑8034, USA [8]Yale Cancer Center, Yale University, 60 College Street, New Haven, CT 06520‑8034, USA
出处:
ISSN:

关键词: Valeric acid HDAC inhibitor Prostate cancer Cancer stemness Apoptosis

摘要:
Prostate cancer is the second cause of cancer-related deaths in men worldwide, and new agents for curing the disease are still needed. In this study, we theoretically and experimentally demonstrated that valeric acid (VA) was a HDAC inhibitor, and anti-cancer efficacy of VA in prostate cancer cells was also observed using either 2D or 3D culture systems. VA was cytotoxic for prostate cancer cells but low toxic to normal cells. VA significantly inhibited E2F1/E2F3 expression but increased CASP3 activity. In vivo mouse models further showed its anti-cancer activity and potential property of chemosensitizer with promoting apoptosis. The findings suggest that VA acts as a HDAC3 inhibitor with anti-cancer effect on prostate cancer by regulating E2F1/E2F3/CASP3 axis.© 2022. The Author(s).

基金:
语种:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2021]版:
大类 | 4 区 医学
小类 | 4 区 肿瘤学
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 肿瘤学
JCR分区:
出版当年[2020]版:
Q3 ONCOLOGY
最新[2023]版:
Q2 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2020版] 出版当年五年平均 出版前一年[2019版] 出版后一年[2021版]

第一作者:
第一作者机构: [1]Department of Chinese Medicine, Naval Medical University, Shanghai 200433, People’s Republic of China [2]Department of Chinese Medicine Oncology, Changhai Hospital affiliated to Naval Medical University, Shanghai 200433, People’s Republic of China [5]Department of Oncology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510405, Guangdong, People’s Republic of China [6]Present Address: Department of Chronic Disease Epidemiology, Yale School of Public Health, Yale University, 60 College Street, New Haven, CT 06520‑8034, USA [7]School of Medicine, Center for Biomedical Data Science, Yale University, 60 College Street, New Haven, CT 06520‑8034, USA [8]Yale Cancer Center, Yale University, 60 College Street, New Haven, CT 06520‑8034, USA
通讯作者:
通讯机构: [1]Department of Chinese Medicine, Naval Medical University, Shanghai 200433, People’s Republic of China [2]Department of Chinese Medicine Oncology, Changhai Hospital affiliated to Naval Medical University, Shanghai 200433, People’s Republic of China [5]Department of Oncology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510405, Guangdong, People’s Republic of China [6]Present Address: Department of Chronic Disease Epidemiology, Yale School of Public Health, Yale University, 60 College Street, New Haven, CT 06520‑8034, USA [7]School of Medicine, Center for Biomedical Data Science, Yale University, 60 College Street, New Haven, CT 06520‑8034, USA [8]Yale Cancer Center, Yale University, 60 College Street, New Haven, CT 06520‑8034, USA
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:2018 今日访问量:0 总访问量:645 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号